Ovid Therapeutics (NASDAQ: OVID)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.210 | -0.230 | -0.0200 | ||||
REV | 1.445M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ovid Therapeutics (NASDAQ: OVID) through any online brokerage.
Other companies in Ovid Therapeutics’s space includes: Graphite Bio (NASDAQ:GRPH), Jounce Therapeutics (NASDAQ:JNCE), Celcuity (NASDAQ:CELC), Immuneering (NASDAQ:IMRX) and Sesen Bio (NASDAQ:SESN).
The latest price target for Ovid Therapeutics (NASDAQ: OVID) was reported by Citigroup on Friday, May 20, 2022. The analyst firm set a price target for 2.40 expecting OVID to rise to within 12 months (a possible 11.37% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Ovid Therapeutics (NASDAQ: OVID) is $2.155 last updated Today at July 5, 2022, 4:33 PM UTC.
There are no upcoming dividends for Ovid Therapeutics.
Ovid Therapeutics’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Ovid Therapeutics.
Ovid Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.